Comparative in vitro metabolic profiling of six novel methylthiophene cathinones using different human liver systems and LC-HRMS/MS

Abstract Synthetic cathinones represent a major class of new psychoactive substances associated with severe toxicological risks. Therapeutic cathinone derivatives such as amfepramone (appetite suppressant) were partially removed from the market due to severe side effects. p -Tolyl-substituted synthetic cathinones are primarily known as new psychoactive substances and are associated with serious adverse events and abuse liability. Bioisosteric replacement of the p -tolyl ring with a 5′-methylthiophene moiety has recently emerged as a structural optimization strategy in this class and has led to the evaluation of methylthiophenes, a novel class of cathinone analogues. Knowledge of their hepatic biotransformation is essential for reliable toxicological detection and risk assessment. This study investigated the in vitro hepatic metabolism of six novel methylthiophene cathinones, 5Me-NM-BT (5-methyl- N -methyl-butanothiophenone), 5Me-NM-VT (5-methyl- N -methyl-valerothiophenone), 5Me-NE-BT (5-methyl- N -ethyl-butanothiophenone), 5Me-NE-VT (5-methyl- N -ethyl-valerothiophenone), 5Me- α P-BT (5-methyl- α -pyrrolidino-butanothiophenone), and 5Me- α P-VT (5-methyl- α -pyrrolidino-valerothiophenone) using pooled human liver microsomes (pHLM), pooled human liver S9 fraction (pHLS9), and HepG2 cells. Metabolites were characterized using reversed-phase and hydrophilic interaction liquid chromatography coupled to high-resolution tandem mass spectrometry. Additionally, recombinant human monooxygenases were screened to identify isoenzymes mediating initial phase I steps. In total, 48 phase I and two phase II metabolites could be tentatively identified. Within each subgroup, the compounds showed similar metabolic profiles. Isozyme mapping revealed consistent contributions of various enzymes, including CYP1A2, CYP2B6, CYP2C19, CYP2D6, and CYP3A4 suggesting a low risk of metabolism-based drug–drug interactions or single-enzyme polymorphism impact. Hydroxylated metabolites at the 5′-methyl group were consistently abundant across all models and, in combination with the respective parent compounds, represent promising analytical targets for toxicological screening.

Authors

Institutions

Publication Details

Journal
Archives of Toxicology
Published
2026-10-31
DOI
https://doi.org/10.1007/s00204-026-04616-4
Primary Topic
Forensic Toxicology and Drug Analysis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Comparative in vitro metabolic profiling of six novel methylthiophene cathinones using different human liver systems and LC-HRMS/MS

Simon D. Brandt, Markus Robert Meyer, Lea Wagmann, Selina Hemmer et al.
Archives of Toxicology
Forensic Toxicology and Drug Analysis
article

Comparative in vitro metabolic profiling of six novel methylthiophene cathinones using different human liver systems and LC-HRMS/MS

Simon D. Brandt, Markus Robert Meyer, Lea Wagmann, Selina Hemmer, Alexandra K. Kiemer, Tilman F. Arnst, Iris E. Weber, Jake Kershaw
article en

Abstract

Abstract Synthetic cathinones represent a major class of new psychoactive substances associated with severe toxicological risks. Therapeutic cathinone derivatives such as amfepramone (appetite suppressant) were partially removed from the market due to severe side effects. p -Tolyl-substituted synthetic cathinones are primarily known as new psychoactive substances and are associated with serious adverse events and abuse liability. Bioisosteric replacement of the p -tolyl ring with a 5′-methylthiophene moiety has recently emerged as a structural optimization strategy in this class and has led to the evaluation of methylthiophenes, a novel class of cathinone analogues. Knowledge of their hepatic biotransformation is essential for reliable toxicological detection and risk assessment. This study investigated the in vitro hepatic metabolism of six novel methylthiophene cathinones, 5Me-NM-BT (5-methyl- N -methyl-butanothiophenone), 5Me-NM-VT (5-methyl- N -methyl-valerothiophenone), 5Me-NE-BT (5-methyl- N -ethyl-butanothiophenone), 5Me-NE-VT (5-methyl- N -ethyl-valerothiophenone), 5Me- α P-BT (5-methyl- α -pyrrolidino-butanothiophenone), and 5Me- α P-VT (5-methyl- α -pyrrolidino-valerothiophenone) using pooled human liver microsomes (pHLM), pooled human liver S9 fraction (pHLS9), and HepG2 cells. Metabolites were characterized using reversed-phase and hydrophilic interaction liquid chromatography coupled to high-resolution tandem mass spectrometry. Additionally, recombinant human monooxygenases were screened to identify isoenzymes mediating initial phase I steps. In total, 48 phase I and two phase II metabolites could be tentatively identified. Within each subgroup, the compounds showed similar metabolic profiles. Isozyme mapping revealed consistent contributions of various enzymes, including CYP1A2, CYP2B6, CYP2C19, CYP2D6, and CYP3A4 suggesting a low risk of metabolism-based drug–drug interactions or single-enzyme polymorphism impact. Hydroxylated metabolites at the 5′-methyl group were consistently abundant across all models and, in combination with the respective parent compounds, represent promising analytical targets for toxicological screening.

Archives of Toxicology
Alexander Shulgin Research Institute (US), Liverpool John Moores University (GB), Saarland University (DE)
Openalex Percentile: Top 14%
Forensic Toxicology and Drug Analysis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon